通用名称

lurasidone hydrochloride

儿科标签批准日期

2019/12/4 0:00:00

特定指示/秒

Postmarketing study

标签更改摘要

- In a long-term, open-label study that enrolled pediatric patients age 6 to 17 years with schizophrenia, bipolar depression, or autistic disorder from three short-term, placebo-controlled trials, 54% (378/701) received lurasidone for 104 weeks. - In this trial, the mean increase in height from open-label baseline to Week 104 was 4.94 cm. The mean change in height z-score indicates a minimal deviation from the normal growth curve. - Postmarketing stud.

治疗类别

Antipsychotics/Schizophrenia

立法类型

PREA Only

产品说明书链接